The top U.S. infectious disease official says concerns over leaks compelled him to reveal data on Gilead Sciences Inc.'s experimental drug remdesivir, the first in a scientifically rigorous clinical trial to show benefit in treating COVID-19.
Some scientists surprised Oval Office used to release preliminary antiviral drug details
Post a Comment